News

Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline

  • Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
    04/30/2024

Biote Schedules First Quarter 2024 Financial Results Release and Conference Call

  • IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Tuesday, May 7, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be a.
    04/23/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Haymaker Acquisition Corp. III (BTMD) can sell. Click on Rating Page for detail.

The price of Haymaker Acquisition Corp. III (BTMD) is 6.01 and it was updated on 2024-05-04 07:00:33.

Currently Haymaker Acquisition Corp. III (BTMD) is in undervalued.

News
    
News

biote Corp. (BTMD) Q4 2023 Earnings Call Transcript

  • biote Corp. (BTMD) Q4 2023 Earnings Call Transcript
    Tue, Mar. 12, 2024

Analysts Estimate biote Corp. (BTMD) to Report a Decline in Earnings: What to Look Out for

  • Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
    Tue, Mar. 05, 2024

biote Should Keep Delivering Strong Growth

  • biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its expansion into complementary wellness products. BTMD is considered undervalued and has an aggressive price target for the end of next year.
    Wed, Nov. 29, 2023

Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates

  • Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago.
    Tue, Nov. 07, 2023

Recent Price Trend in biote Corp. (BTMD) is Your Friend, Here's Why

  • If you are looking for stocks that are well positioned to maintain their recent uptrend, biote Corp. (BTMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
    Tue, Jul. 18, 2023
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

biote Corp. (BTMD) Moves 5.3% Higher: Will This Strength Last?

  • biote Corp. (BTMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  • 07/12/2023

Biote Schedules First Quarter 2023 Financial Results Release and Conference Call

  • IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023, after the close of the market. A conference call to discuss the firm's results will be held Wednesday, May 10, 2023, at 8:30 a.m. ET. Conference Call Details The conference call may be accessed by dialing (844) 481-.
  • 04/26/2023

Does biote Corp. (BTMD) Have the Potential to Rally 82.51% as Wall Street Analysts Expect?

  • The mean of analysts' price targets for biote Corp. (BTMD) points to an 82.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  • 03/31/2023

Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call

  • IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. A conference call to discuss the firm's results will be held Wednesday, March 29, 2023 at 8:30 a.m. ET.
  • 02/09/2023

Biote Schedules Third Quarter 2022 Financial Results Release and Conference Call

  • IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide third quarter financial results on Tuesday, November 8, 2022, after the close of the market.
  • 10/31/2022

Biote to Report Second Quarter 2022 Financial Results on August 9, 2022 and Host Conference Call on August 10, 2022

  • IRVING, Texas--(BUSINESS WIRE)--biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022, after market close on Tuesday, August 9, 2022. Terry Weber, Chief Executive Officer, and the Company's management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, August 10
  • 07/20/2022
Unlock
BTMD Ratings Summary
BTMD Quant Ranking